NAGE vs TRLV
Niagen Bioscience, Inc. and Trulieve Cannabis Corp., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | NAGE | TRLV |
|---|---|---|
| Revenue | $129.4M | $1.2B |
| Net income | $17.4M | $-122.2M |
| Gross margin | 64.3% | 60.2% |
| Net margin | 13.4% | −10.3% |
| Return on equity | 28.3% | −10.2% |
| Diluted EPS | $0.20 | −$0.58 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | $228.6M |
| Equity | $76.5M | · |
| Net debt / equity | · | −0.10× |
| Current ratio | 4.86× | 4.43× |
| Revenue CAGR 5y | 16.9% | 17.8% |
| Profit CAGR 5y | · | · |
TRLV bills 9.1× the revenue of NAGE, and TRLV closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | NAGE | TRLV |
|---|---|---|
| FY2025 | $129.4M | $1.2B |
| FY2024 | $99.6M | $1.2B |
| FY2023 | $83.6M | $1.1B |
| FY2022 | $72.0M | $1.2B |
| FY2021 | $67.4M | $931.9M |
| FY2020 | $59.3M | $521.5M |
| FY2019 | $46.3M | $252.8M |
Bottom line
| Fiscal year | NAGE | TRLV |
|---|---|---|
| FY2025 | $17.4M | $-122.2M |
| FY2024 | $8.6M | $-160.6M |
| FY2023 | $-4.9M | $-533.1M |
| FY2022 | $-16.5M | $-252.7M |
| FY2021 | $-27.1M | $17.4M |
| FY2020 | $-19.9M | $63.0M |
| FY2019 | $-32.1M | $53.1M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$1,051,757,000 | TRLV |
| FY2024 | −$1,086,893,000 | TRLV |
| FY2023 | −$1,045,623,000 | TRLV |
| FY2022 | −$1,146,179,000 | TRLV |
| FY2021 | −$864,485,000 | TRLV |
| FY2020 | −$462,276,000 | TRLV |
| FY2019 | −$206,528,000 | TRLV |
TRLV has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 16 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +23.8 pp | NAGE |
| FY2024 | +22.1 pp | NAGE |
| FY2023 | +41.3 pp | NAGE |
| FY2022 | −2.2 pp | TRLV |
| FY2021 | −42.1 pp | TRLV |
| FY2020 | −45.7 pp | TRLV |
| FY2019 | −90.4 pp | TRLV |
The higher net margin has changed hands between NAGE and TRLV over this period.
7 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NAGE's net margin has been more volatile than TRLV's over the 7 comparable fiscal years — 27.2 percentage points of standard deviation against 21.0.
7 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between NAGE and TRLV over these 7 fiscal years — NAGE led in 3 and TRLV in 4.
7 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NAGE's return on equity has been more volatile than TRLV's over the 7 comparable fiscal years — 62.1 percentage points of standard deviation against 22.3.
7 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between NAGE and TRLV over these 7 fiscal years — NAGE led in 3 and TRLV in 4.
7 of 16 comparable fiscal years — a year missing data on either side is not counted.